Federal Circuit schedules May 11, 2026 oral argument for Enanta's patent appeal against Pfizer over Paxlovid

ENANTA PHARMACEUTICALS INC

Federal Circuit oral argument in Enanta's patent appeal against Pfizer (Paxlovid) set for May 11, 2026.
Enanta originally filed suit for infringement of U.S. Patent No. 11,358,953 related to Paxlovid.
Notice of appeal was filed on February 3, 2025.
The appeal is before the U.S. Court of Appeals for the Federal Circuit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.